Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Geron Corp. GERN

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-83.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.2 · Net income -184.1
15M30M-100M-200M
2009201220152018202120242025
Compound annual growth
−2.2%
−26.0%
−15.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −26.0% a year over the five years to FY2023.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -81832.9% · Net ·
-50000%
200920172025
ROE
FY2025 · ROE -33.0%
-50%-100%
200920172025
Three returns, three denominators.

Each USD of equity lost 33 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -219.3
-100M-200M
200920172025

Total assetsUSD 570.5M
EquityUSD 225.9M
CashUSD 77.6M
Gross debtUSD 119.5M
Net debtUSD 42.0M
Current ratio4.66×

Net debt stands at 19% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
GERN, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B◌◌0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.1−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.1−0.1−0.1
EBITDA $B◌◌◌◌◌−0.1−0.1−0.0−0.0−0.0−0.0◌◌◌◌◌◌
Income tax $B0.00.00.0◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.1−0.2−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.00.0−0.0−0.0−0.1−0.1−0.1−0.1
Free cash flow $B◌−0.2−0.2−0.1−0.1−0.1−0.0−0.0◌−0.0−0.00.0−0.0−0.1−0.1−0.0−0.0
EPS, diluted $−0.13−0.27−0.32−0.37−0.35−0.28−0.36−0.15−0.18−0.190.00−0.23−0.30−0.54−0.78−1.14−0.80
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %——————————0−0−0————
ROE %−33.0−66.1−112.3−137.5−68.8−43.7−43.8−19.2−24.7−22.30.0−37.5−52.8−59.3−57.1−61.0−40.7
Shares out B0.640.610.540.390.320.310.200.190.160.160.160.160.130.130.130.12◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 64 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image